“Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s46, https://doi.org/10.25251/skin.4.supp.46.